Clinical trials: Dose Finding Study
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by…
- Trial name
- NCT02556801
- Testing
- SUBLIVAC FIX Phleum Prat.
- Where
- Canada
- Volunteers
- 168 people
- Sponsor
- HAL Allergy
CNS Lesion, Blood Brain Barrier Defect
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at…
- Trial name
- NCT02633501
- Testing
- P03277, Gadobenate dimeglumine, MRI
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 312 people
- Sponsor
- Guerbet
Ovarian Cancer
Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Advanced ovarian cancer is a high medical need indication. Cure is not available to these patients and treatment has palliative intent.
- Trial name
- OVAR (NCT02054351)
- Testing
- IMAB027
- Where
- 9 sites in Belgium, Germany
- Volunteers
- 42 people
- Sponsor
- Ganymed Pharmaceuticals GmbH
Recurrent Platinum-resistant Ovarian Cancer
Dose-finding Study in Platinum-Resistant Ovarian Cancer
Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer.
- Trial name
- NCT01653912
- Testing
- GSK2110183 in combination with carboplatin and paclitaxel
- Where
- 10 sites in Australia, Russia and 1 more
- Volunteers
- 59 people
- Sponsor
- Accenture
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Dyslipidemia
A Study in People With Abnormal Fat Levels in the Blood
The purposes of this study are to determine: The safety of the study medication and any side effects that might be associated with it; Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C)…
- Trial name
- NCT00116519
- Testing
- PPAR alpha
- Where
- 54 sites in United States
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that…
- Trial name
- NCT05614102
- Testing
- BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 284 people
- Sponsor
- Bayer
Pregnancy, Contraception
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive effect when injected every 6 months.
- Trial name
- NCT02817464
- Testing
- TV-46046 - 400 mg/mL, TV-46046 - 200 mg/mL
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Infections and Infestations, Pulmonary Tuberculosis
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose…
- Trial name
- DECODE (NCT04550832)
- Testing
- Delpazolid, Bedaquiline, Delamanid, Moxifloxacin
- Where
- 5 sites in South Africa, Tanzania
- Volunteers
- 76 people
- Sponsor
- LigaChem Biosciences, Inc.
Chronic Pain, Neck Pain
A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.
- Conditions
- Chronic Pain, Neck Pain, Back Pain, Pain
- Trial name
- CYDEPS (NCT04976738)
- Testing
- Cybis™ 10:25 THC:CBD oil
- Where
- 2 sites in Australia
- Volunteers
- 28 people
- Sponsor
- Cymra Life Sciences
Solid Tumors
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without food and without any rest periods, as long as there is no evidence of disease progression or unacceptably severe…
- Trial name
- NCT01049893
- Testing
- Compound AC220
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Daiichi Sankyo
Anemia, Solid Tumors
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
The purpose of this study is to assess the safety of NESP administered by SC injection in subjects with solid tumours and anaemia receiving multicycle chemotherapy.
- Trial name
- NCT00540384
- Testing
- Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
- Volunteers
- 405 people
- Sponsor
- Amgen
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Liver Diseases, Alcoholic
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.
- Trial name
- ALLSTAR (NCT07791043)
- Testing
- Efimosfermin alfa
- Where
- 4 sites in United States, Argentina
- Volunteers
- 274 people
- Sponsor
- GlaxoSmithKline
Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery, Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade
Background context: Amogammadex sodium has completed Phase I-III clinical studies in China for reversal of rocuronium-induced blockade. No clinical studies have yet been conducted for vecuronium-induced blockade.
- Trial name
- NCT07595393
- Testing
- Rocuronium (0.6mg/kg), vecuronium bromide (0.1mg/kg)
- Volunteers
- 64 people
- Sponsor
- Amckaus PTY LTD.
Erythematotelangiectatic Rosacea
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single…
- Trial name
- NCT00989014
- Testing
- CD07805/47
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Galderma R&D
Nasal Congestion Due to Allergic Rhinitis
Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study
The researchers in this study want to find out whether participants with a history of stuffy nose due to allergic reactions in the nose would intend to buy drug Phenylephrine Hydrochloride (Phenylephrine HCl) extended release…
- Trial name
- NCT04534452
- Testing
- Phenylephrine HCl (Sinus Comfort, BAY112476)
- Where
- United States
- Volunteers
- 347 people
- Sponsor
- Bayer
Neoplasms
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
The primary objective of this trial is: Part I To determine Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI 836880 monotherapy Part II To determine MTD and/or RP2D of the combination therapy of BI 836880…
- Trial name
- NCT03972150
- Testing
- BI 836880, BI 754091
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Influenza, Human
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A)…
- Trial name
- NCT05823974
- Testing
- F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z
- Where
- 41 sites in United States, Belgium and 2 more
- Volunteers
- 1,275 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
NAFLD, Diabetes Mellitus, Type 2
Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
- Trial name
- NCT03371355
- Testing
- ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
- Where
- 42 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Akcea Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.